Artiva Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTV research report →
Range $35 – $40
Price Chart
About the company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
- CEO
- Fred Aslan
- IPO
- 2024
- Employees
- 115
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ARTV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $355.43M
- P/E
- -2.20
- PEG
- -0.66
- P/S
- 0.00
- P/B
- 0.82
- EV/EBITDA
- -0.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.86%
- ROIC
- -26.91%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-2,597,000-1134.7%
- Op Income
- $-90,610,000
- Net Income
- $-83,865,000-43.4%
- EPS
- $-3.43+34.0%
- OCF Growth
- -39.5%
- FCF Growth
- -42.5%
- 52W High
- $14.53
- 52W Low
- $2.71
- 50D MA
- $10.07
- 200D MA
- $7.88
- Beta
- 2.41
- RSI (14)
- 32
- Avg Volume
- 400.56K
No earnings-call transcripts are available for ARTV yet.
- Free Float
- 39.8%
- Shares Outstanding
- 48.89M
- Float Shares
- 19.45M
of shares held by institutions
40 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 17.96M | ▲ 8.10M |
| Viking Global Investors LP | 2.60M | ▲ 2.60M |
| Blackstone Inc. | 2.40M | ▲ 2.40M |
| 5am Venture Management, LLC | 2.35M | 0 |
| Vr Adviser, LLC | 2.04M | ▲ 434.03K |
| Franklin Resources Inc | 2.00M | ▲ 1.48M |
| Caligan Partners LP | 1.74M | ▲ 1.74M |
| Vanguard Capital Management LLC | 981.82K | ▲ 774.13K |
| Samsara Biocapital, LLC | 954.86K | ▲ 954.86K |
| Blue Owl Capital Holdings LP | 874.54K | ▲ 874.54K |
| Propel Bio Management, LLC | 696.44K | ▲ 550.07K |
| Blackrock, Inc. | 694.73K | ▲ 481.34K |
Held by 80 ETFs
Biggest fund positions in ARTV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 5, 26 | Horan Christopher | sell | 10,340 |
| Oct 5, 26 | Bush Jennifer | sell | 8,370 |
| Oct 5, 26 | Banerjee Subhashis | sell | 1,099 |
| Oct 5, 26 | Aslan Fred | sell | 61,696 |
| Sep 15, 26 | Aslan Fred | other | 110,000 |
| Sep 15, 26 | Aslan Fred | other | 315,000 |
| Sep 10, 26 | Aslan Fred | other | 45,000 |
| Sep 10, 26 | Aslan Fred | other | 155,000 |
| Sep 10, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 16,250 |
| Sep 10, 26 | Stoppel Laura | other | 16,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARTV coverage
Recent articles, reports, and earnings notes.
No research on ARTV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARTV report →Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
globenewswire.com · Oct 2
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
globenewswire.com · Oct 1
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease
globenewswire.com · Sep 23
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com · Sep 17
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
globenewswire.com · Sep 8
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
globenewswire.com · Sep 2
2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC
defenseworld.net · Aug 26
Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)
defenseworld.net · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.